Lexaria Bioscience (LEXX) Raw Materials (2018 - 2019)
Lexaria Bioscience's (LEXX) quarterly Raw Materials came in at $40675.0 in Q1 2019, up 38.56% quarter-over-quarter from $29355.0 in Q3 2018.
Lexaria Bioscience (LEXX) Raw Materials (2018 - 2019) Analysis & Trends
Lexaria Bioscience has disclosed Raw Materials across 2 years of filings, most recently posting $40675.0 for Q1 2019.
- Raw Materials for Q1 2019 came in at $40675.0, changed N/A year-over-year; the trailing twelve-month figure through Feb 2019 was $40675.0 (changed N/A YoY), and the FY2018 annual result was $29355.0, changed N/A from the prior year.
- Raw Materials came in at $40675.0 for Q1 2019 at Lexaria Bioscience, up from $29355.0 in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $40675.0 in Q1 2019 to a low of $29355.0 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Lexaria Bioscience | 7.17 Mn | 1.65 Mn | 20,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2019 | 40,675.00 |
| Aug 31, 2018 | 29,355.00 |